Monday, June 06, 2005 12:19:18 PM
want to give a chemotherapeutic agent to a person unless you're going to
get a positive response. We've been collecting samples all along, but we
just now are in the process of enrolling an additional 100 patients into
a trial at the Moffitt Center, and over the next six to nine months
we'll be finalizing the data. Our goal is to be able to go to the FDA
and show them how important genetic ancestry is. When we originally
looked at the data on a prospective basis of patient populations, we
couldn't make sense of it. That's part of the problem with gene data, no
matter what technology you are using. If you don't understand the
ancestry, or the genetic inheritance that goes along with that data,
it's very difficult puzzle to solve because hundreds and hundreds of
genes need to be analyzed. We're not claiming that we have the end-all-
and-be-all answer, but we certainly have what we think is a reasonable
tool for analyzing that very complex data.
The Goal is 6 to 9 Months---GEO
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM